Enlitic has signed a binding conditional agreement to acquire Laitek, a medical imaging data migration and routing service provider based in the US and Romania. Enlitic anticipates that the deal, valued at $4.95 million, will mark a new phase of growth for the company, with Michael Sistenich, CEO, stating that the two companies are “a strong strategic fit, allowing the provision of a differentiated and synergistic service offering.”
Why we are covering this topic
- To date, Enlitic has focused on data standardisation, which plays a pivotal role in realising the value of the vast quantities of data generated by healthcare providers. Despite the importance of this process, it has proven to have limited commercial viability for Enlitic, as demonstrated by the low revenues reported during the company’s IPO.
- The acquisition of Laitek represents a key strategic shift for Enlitic, expanding the scope of its offering to include more tangible services.
Why it matters
- There are considerable opportunities for Enlitic’s data standardisation capabilities in the long term, particularly in the development and training of clinical AI and the pharmaceutical sector.
- However, the company requires more immediate financial stability to ensure it can capitalise on these prospects.
Read the full insight with a Signify Premium Insights - Healthcare IT subscription